Objectives: The goal of this study was to review the feasibility of local bivalirudin injection for adjunct treatment of venous congestion of head and neck reconstructive flaps. Conclusions: Bivalirudin is a safe and feasible adjunct therapy for treatment of flap congestion. It may serve as a useful alternative to traditional leech therapy, as bivalirudin negates the need for antibiotic prophylaxis, eliminates the psychological aversion associated with leech therapy, and avoids the potential for leech migration. Further work to determine the efficacy of bivalirudin to standard leech therapy is warranted.
poor perforators, excessive fluid administration, dependency, and lymphedema (Hand et al., 2015; Urken et al., 1994) . Some cases of venous congestion have been successfully managed using adjuvant leech therapy (Whitaker et al., 2005 (Whitaker et al., , 2012 . Leeches release many active salivary products including hirudin, a tremendously potent natural anticoagulant, thereby promoting bleeding and the relief of venous congestion (Whitaker et al., 2005) . Leech therapy, however, is associated with an increased risk of blood transfusions, (Whitaker et al., 2012) infection (Kruer, Barton, Roberti, Gilbert, & McMillian, 2015; Whitaker et al., 2011 Whitaker et al., , 2012 , and leech migration (Whitaker et al., 2005) , as well as psychological aversion on behalf of the patient (Chepeha, Nussenbaum, Bradford, & Teknos, 2002; Whitaker et al., 2011) .
Recombinant hirudin derivatives, such as bivalirudin, act in a similar fashion to their parent compound and are used for anticoagulation during coronary angiogplasty (Di Nisio, Middeldorp, & Buller, 2005) and for prophylaxis against deep vein thrombosis (Ginsberg et al., 1994) .
Bivalirudin is a direct inhibitor of thrombin (which activates both platelets and other clotting factors), thereby leading to an inhibition of the clotting cascade (Di Nisio et al., 2005) . Additionally, local injection of natural or recombinant hirudin directly into congested flaps have revealed evidence of improved flap survival in rat (Ying-Xin, Guo-Qian, Jia-Quan, & Han, 2012) , rabbit (Duzgun, Nisanci, & Unlu, 2014) , and pig models (Guo-Qian, Gang, & Zhi-Yong, 2012; Zhao, Shi, Sun, Yin, & Yang, 2012) . The extent to which recombinant hirudin, such as bivalirudin, may aid in relief of venous congestion in head and neck reconstructive flaps in patients has not previously been studied.
In this study, we review the feasibility of the use of local injection of bivalirudin into flaps used for head and neck reconstruction with venous congestion. We hypothesized that bivalirudin will be safe and easy to administer to reduce venous congestion and may be an acceptable alternative adjunct therapy. To our knowledge, this represents the first evaluation of the potential use of bivalirudin for venous congestion of reconstructive flaps in humans. 
| P A TIE NT S A ND M E TH ODS

| Bivalirudin treatment
Bivalirudin was injected intradermally at a dose of 0.3 milligrams per kilogram directly into the reconstructive flap by a member of the surgical team, and a small 1 cm bleb was raised ( Figure  F1  1A ). A #15 blade was then used to make a cruciate cut over the bleb to allow for passive bleeding from the incision ( Figure 1B ). Anywhere from 1 to 4 areas of the flap were injected at a time depending on the size of the flap and areas of venous congestion. Gauze dressing was usually placed over the bleeding sites to collect the blood and prevent drainage into the pharynx or tracheostoma. A data sheet was placed at bedside to record the frequency, number, and duration of injections.
The duration of passive bleeding and the presence of signs of venous congestion of the flap determined the frequency of bivalirudin doses. The maximum frequency of bivalirudin administration was every six hours. The dose was selected based upon previously published success when used for deep vein thrombosis prophylaxis (Ginsberg et al., 1994) . Given its anticoagulant properties (Di Nisio et al., 2005) , all patients had a baseline complete blood count (CBC) and coagulation profile before administration. Also, given that bivalirudin is cleared by the kidneys (Tsu & Dager, 2011) , all patients had a baseline basic meta- The description of the bivalirudin cases is presented in Table  T1 1. (Rados, 2004) . Leech therapy is now commonly used to help alleviate flap venous congestion (Whitaker et al., 2005 (Whitaker et al., , 2012 . In addition to actively removing blood volume by ingestion, leeches release many salivary byproducts that lead to protein breakdown, vasodilation, and decreased platelet aggregation, all of which promote passive bleeding which may last for hours after the leech has engorged and unlatched (Whitaker et al., 2005) .
Nonetheless leech therapy may have several drawbacks, such as psychological aversion (Chepeha et al., 2002) and risk of infection, (Kruer et al., 2015; Whitaker et al., 2012) which has led investigators to search for alternate therapies.
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Several alternatives to medicinal leeching for the treatment of venous congestion have been proposed (Cottler & Skalak, 2001; Iglesias & Butron, 1999; Russell, Connor, & Hartig, 2010) . Pharmacologic leeching with the delivery of nitrous oxide to flap tissue, for instance, has shown improvement of flap perfusion and survival in rats (Russell et al., 2010) .
So-called mechanical leech devices have also been developed. Hartig et al. (2003) described a small glass suction device that can be placed over compromised flap tissue. The device is then coupled to a heparinimpregnated subcutaneous disk and can be manually turned to allow for mechanical anticoagulation, and a continuous heparin irrigation system promotes passive bleeding. It was found to have similar efficacy as leech therapy in improving perfusion in venous compromised flaps in a porcine model . The use of mechanical leech devices has also been described in rats (Cottler & Skalak, 2001 ). The effect that such devices may help in compromised reconstruction flaps in patients, however, is not known. The use of local heparin administration has been described to treat venous congestion in re-implanted digits with some success (Iglesias & Butron, 1999) . The distal tip of digits, for instance, may have a tenuous blood supply given the small size and distribution of vessels (Kim, Yang, Lee, Ki, & Roh, 2013) . Therefore, local Zhao et al., 2012) . Furthermore, intravenous injection of recombinant hirudin in regional flaps in rabbits has been reported to increase surface area survival compared with injection of low molecular weight heparin or no injection (Duzgun et al., 2014) . Our current report builds on this preclinical experience and, to our knowledge, is the first case series to describe the use of bivalirudin in humans in the management of flap venous congestion.
Bivalirudin treatment for an adjunct treatment of venous congestion in head and neck reconstructive flaps may have several advantages over standard leech therapy. For instance, leech therapy requires the use of prophylactic antibiotics in order to protect against infection (Kruer et al., 2015; Whitaker et al., 2012) . Nonetheless, infection may occur despite the use of antibiotics. In one systematic review of leech therapy in reconstructive flaps, a pooled infection rate of 14.4% was reported and was associated with decreased flap survival (Whitaker et al., 2012) . The majority of these cases were found to harbor Aeromonas hydrophila, a common leech pathogen (Whitaker et al., 2011) .
Moreover, infections acquired during leech therapy may be secondary to an increase in drug resistance (Kruer et al., 2015) . The use of bivalirudin negates the need for prophylactic antibiotics and may decrease the risk of surgical site infection.
There are other advantages of avoiding the use of live leeches.
Leech migration has been reported (Martin et al., 2013) and is a very real concern for intraoral flaps. One technique to avoid this is to place a suture ("leash") through the leech's tail and tape it to the neck or chest. Leeches that migrate and are "lost" require an intensive and expensive work-up to confirm that they have not latched-on in the pharynx, esophagus or trachea as this could result in potential obstruction of the airway or continued blood loss (Whitaker et al., 2005) . Psychological aversion with the use of leeches has also been reported (Chepeha et al., 2002) . We have appreciated this in patients, family members, and nurses who handle the leeches, especially when placed intraorally. Bivalirudin, therapy, therefore, may eliminate these difficulties if utilized as an alternative.
We found that bivalirudin was safe to administer to our patient population. As is customary for any patient intentionally treated with blood-letting, meticulous attention to fluid shifts, red blood cell counts, and electrolytes is mandatory. Reports have shown the need for blood transfusion with live leech therapy may occur in up to 100% of the patients (Chepeha et al., 2002) . Only two of the participants in our current series required blood transfusions during therapy. Although we
were not able to measure objective blood loss in this study, this may indicate that our group experienced less blood loss than occurs with traditional leech therapy. Whether this is a reflection of the lack of the active component of leech therapy with bivalirudin injection or reflects a less aggressive treatment protocol in our institution in the nascent phase of this novel treatment is unknown at this point.
Our overall flap salvage rate (80% with at least partial salvage) is similar to what has been previously reported in the literature for standard leech therapy. A systematic review for the efficacy of leeches in improving venous congestion for plastic reconstructive flaps or reimplantation surgery reported the overall success rate for at least partial survival of the reconstructive site at 79% (Whitaker et al., 2012) . It is unclear, however, to what extent our flap salvage was based solely on bivalirudin treatment, as the majority of our injections were used as adjunct therapy with other routine flap salvage techniques and our patient population was not treated in a standard manner. As we continue to investigate bivalirudin's potential role, its efficacy on improving venous congestion in heterogenous patient populations will need to be determined. The ease of administration and tolerability of the therapy in comparison to leeching make it an attractive alternative.
One primary deterrent from using bivalirudin injection is its records, which may be inaccurate and poorly documented although we did attempt to use a standardized data form for all patients. Also, our small sample size, and lack of control group does not allow us to compare bivalirudin treatment to standard leech therapy or to no therapy at all. We could not control for confounding variables (such as age, comorbidities, etc.) and patients were not treated in a standard fashion.
We present a heterogeneous patient population, reconstructed with various head and neck flaps, which limits generalizability of our results.
Therefore, the incremental gain of bivalirudin injection to flap salvage remains unknown. A randomized controlled trial comparing bivalirudin to other treatment methods of venous congestion is needed to further determine its potential role but admittedly would be very difficult to perform given the rarity of the situation and heterogeneous patient group. Additionally, bivalirudin for the adjunct treatment of venous congestion is an off-label use of the medication, and therefore all patients should be informed about its risks and benefits and provide consent before its use. Alternative administrative routes and doses for bivalirudin (e.g., intravenous delivery) methods should be studied as these may improve flap salvage rates. Furthermore, we emphasize that first-line management of vascular compromise still remains surgical exploration of the flap pedicle. Bivalirudin, conversely, may be considered in addition to operative and other treatments to address persistent venous congestion, particularly in a subset of patients with psychological aversion and with intraoral flaps in which leech therapy may be difficult to administer. However, more investigation beyond this initial report is needed to understand its efficacy.
| C ONC LUSI ON S
In summary, we describe the feasibility of the use of bivalirudin injection as an alternative adjunct therapy for the treatment of venous congestion in head and neck reconstructive flaps. It may have several benefits over standard leech therapy and therefore its use warrants further investigation.
